Tags: Cancer | Revlimid | lymphoma | drug | celgene | cancer

Revlimid: New Weapon Against Lymphoma

Thursday, 06 Jun 2013 11:35 AM

 

Celgene Corp said that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine.

The U.S. Food and Drug Administration approved Revlimid to treat mantle cell lymphoma (MCL) - a type of non-Hodgkin's lymphoma - that has relapsed or progressed following two prior treatment regimens, one of which must include Takeda Pharmaceutical Co's Velcade.
 
"There remains a tremendous unmet need for patients with previously treated mantle cell lymphoma," Dr. Andre Goy, chairman and director and chief of lymphoma at the John Theurer Cancer Center in Hackensack, New Jersey, said in a statement.
 
Revlimid, which will be the first oral treatment for MCL, is already approved to treat multiple myeloma and the blood disorder myelodysplastic syndromes.
 
The medicine had sales of $1 billion in the first quarter for the U.S. biotechnology company.
Despite the unmet need cited by doctors, analysts predicted only a modest revenue boost for Revlimid from the new indication. Cowen and Co analyst Eric Schmidt forecast additional annual sales of about $100 million to $200 million from the additional approval, saying it was not likely to provide a boost to Celgene's shares.
 
MCL accounts for about 6 percent to 7 percent of total non-Hodgkin's lymphoma cases, or about 11,000 cases, the company said.

© 2015 Thomson/Reuters. All rights reserved.

Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Drug for Low Thyroid Condition

Tuesday, 27 Jan 2015 12:41 PM

A new drug has been approved to raise calcium levels in patients with low thyroid conditions. The U.S. Food and Drug Adm . . .

Combo Blood Pressure Medication

Tuesday, 27 Jan 2015 12:34 PM

A new combination pill to treat people with high blood pressure has won approval from the U.S. Food and Drug Administrat . . .

Generic Nexium Approved

Monday, 26 Jan 2015 16:24 PM

The U.S. Food and Drug Administration said it approved Teva Pharmaceutical's generic version of AstraZeneca's blockbuste . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved